Abstract
An orally absorbed mast cell stabiliser (BRL-10833) has been compared with placebo in a double-blind controlled trial in twenty-five patients with ulcerative colitis; patients received each treatment for one month. There was no significant clinical improvement in symptoms or sigmoidoscopic findings with the drug but there was significant improvement in the histological appearance of rectal biopsies during active treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
